Testing FH-006 vs. chemo for advanced esophageal cancer
This study is testing a new drug, FH-006, against the doctor's choice of chemotherapy for people with advanced esophageal cancer that has worsened after previous treatment with a PD-1/PD-L1 inhibitor plus platinum-based chemo. The goal is to see if FH-006 works better than standard chemo options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 75 years
- ECOG performance status 0 or 1
- Life expectancy of at least 3 months
- Confirmed esophageal squamous cell carcinoma
- Progression after prior PD-1/PD-L1 inhibitor plus platinum chemotherapy
- At least one measurable lesion per RECIST 1.1
- Adequate bone marrow and organ function
- No recent anti-cancer therapy within 4 weeks
- Recovery from previous treatment side effects to grade 1 or less
- No history of serious gastrointestinal or bleeding issues
- No active brain or spinal cord metastases
- No severe heart or blood vessel disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a new form of chemotherapy (docetaxel albumin-bound), an immunotherapy (SG001), and standard chemotherapy (cisplatin) plus radiation for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
This trial tests a new drug called YL201 against standard chemotherapy for people with advanced esophageal squamous cell carcinoma that has gotten worse after one prior treatment. The goal is to see if YL201 works better at controlling the cancer.
This trial tests a new combination of drugs (SYS6010, enlonstobart, and chemotherapy) as a first treatment for people with advanced esophageal cancer that has not spread elsewhere. It aims to find a more effective option for patients who have not received prior therapy for their advanced disease.
This study compares a new drug called SYS6010 with standard chemotherapy for advanced esophageal squamous cell carcinoma that has progressed after prior treatment. It may be an option if you have this specific type of esophageal cancer and are looking for a new treatment approach.
Hear when a new Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.